

CITATION REPORT

List of articles citing

Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use

DOI: 10.1208/s12249-017-0892-0
AAPS PharmSciTech, 2018, 19, 489-511.

Source: <https://exaly.com/paper-pdf/69587484/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
6	Investigation of quality review issues and the association with application characteristics for new drug applications in first-cycle reviews. <i>Regulatory Toxicology and Pharmacology</i> , 2019 , 108, 104448	3.4	
5	Biosimilars: development and investigation using achievements in modern biotechnology. <i>Diabetes Mellitus</i> , 2021 , 23, 548-560	1.6	1
4	Analysis of the Regulatory Science Applied to a Single Portfolio of Eight Biosimilar Product Approvals by Four Key Regulatory Authorities. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	0
3	Biosimilars: evolution of approaches to the development, regulation, life cycle control and interchangeability management. <i>Remedium Journal About the Russian Market of Medicines and Medical Equipment</i> , 2021 , 56-68	0.9	
2	Common deficiencies found in generic Finished Pharmaceutical Product (FPP) applications submitted for registration to the South African Health Products Regulatory Authority (SAHPRA).. <i>Journal of Pharmaceutical Policy and Practice</i> , 2022 , 15, 6	3.2	0
1	Outcomes and endpoints in clinical trials supporting the marketing authorisation of treatments in paediatric acute lymphoblastic leukaemia. <i>Drug Discovery Today</i> , 2022 ,	8.8	